Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版

Ahead of print
Authors' Accepted
Current Issue
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us

Resources & Services

Email alert

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the

AJA Club (in English)
AJA Club (in Chinese)


Volume 24, Issue 2 (March 2022) 24, 180–185; 10.4103/aja202188

Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence

Xian-Yan-Ling Yi1, De-Hong Cao1, Ping-Hong You2, Xing-Yu Xiong1, Xiao-Nan Zheng1, Ge Peng3, Da-Zhou Liao1, Hong Li1, Lu Yang1, Jian-Zhong Ai1

1 Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China
2 Department of Urology, People's Hospital of Deyang City, Deyang 618000, China
3 Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu 610041, China

Correspondence: Dr. L Yang (wycleflue@163.com) or Dr. JZ Ai (jianzhong.ai@scu.edu.cn)

Date of Submission 22-Apr-2021 Date of Acceptance 21-Oct-2021 Date of Web Publication 28-Dec-2021


Neoadjuvant chemotherapy (NAC) has shown promising results in patients with locally advanced penile cancer. However, no consensus exists on its applications for locally advanced penile cancer. Thus, it is unclear which kind of chemotherapy regimen is the best choice. Consequently, a systematic search of PubMed, Web of Science, and EMBASE was performed in March 2021 to assess the efficacy and safety of NAC for the treatment of patients with locally advanced penile cancer. The Newcastle–Ottawa Scale was used to assess the risk of bias in each study. This study synthesized 14 published studies. The study revealed that patients who achieved an objective response to NAC obtained a better survival outcome compared with those who did not achieve an objective response. In addition, the objective response rates (ORRs) and pathological complete response (pCR) rates were 0.57 and 0.11, respectively. The incidence of grade ≥3 toxicity was 0.36. Subgroup analysis found that the ORR and pCR of the taxane–platinum (TP) regimen group performed better than those of the nontaxane–platinum (NTP) regimen group (0.57 vs 0.54 and 0.14 vs 0.07, respectively). Moreover, the TP regimen group had more frequent toxicity than the NTP regimen group (0.41 vs 0.26). However, further studies were warranted to confirm the findings.

Keywords: chemotherapy regimen; locally advanced penile cancer; neoadjuvant chemotherapy; response rate

Full Text | PDF |

Browse:  390
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved